Mind Medicine (MindMed) Inc
F:MMQ

Watchlist Manager
Mind Medicine (MindMed) Inc Logo
Mind Medicine (MindMed) Inc
F:MMQ
Watchlist
Price: 6.785 EUR 1.8% Market Closed
Market Cap: 487.7m EUR
Have any thoughts about
Mind Medicine (MindMed) Inc?
Write Note

Mind Medicine (MindMed) Inc
Other

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Mind Medicine (MindMed) Inc
Other Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Other CAGR 3Y CAGR 5Y CAGR 10Y
Mind Medicine (MindMed) Inc
F:MMQ
Other
$506k
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Johnson & Johnson
NYSE:JNJ
Other
-$1.7B
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Bristol-Myers Squibb Co
NYSE:BMY
Other
-$62m
CAGR 3-Years
N/A
CAGR 5-Years
-10%
CAGR 10-Years
N/A
Pfizer Inc
NYSE:PFE
Other
-$504m
CAGR 3-Years
N/A
CAGR 5-Years
6%
CAGR 10-Years
N/A
Merck & Co Inc
NYSE:MRK
Other
-$333m
CAGR 3-Years
N/A
CAGR 5-Years
-4%
CAGR 10-Years
N/A
Eli Lilly and Co
NYSE:LLY
Other
-$476.7m
CAGR 3-Years
-12%
CAGR 5-Years
-13%
CAGR 10-Years
N/A
No Stocks Found

Mind Medicine (MindMed) Inc
Glance View

Market Cap
487.7m EUR
Industry
Pharmaceuticals

Mind Medicine (MindMed), Inc. operates as clinical stage biopharmaceutical company, which engages in developing novel product candidates to treat brain health disorders. The company is headquartered in New York City, New York. The company went IPO on 2015-05-04. The firm is engaged in developing products to treat brain health disorders. The company is developing a pipeline of product candidates, with and without acute perceptual effects, targeting neurotransmitter pathways. This specifically includes pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM-120 and MM-402, the Company's product candidates. MM-120 is a pharmaceutically optimized form of lysergide D-tartrate that the Company is developing for the treatment of generalized anxiety disorder (GAD). MM-120 is also being studied in a subperceptual repeat administration dosing regimen for the treatment of attention deficit hyperactivity disorder (ADHD). MM-402, also referred to as R(-)-MDMA, is the Company's form of the R-enantiomer of 3,4-methylenedioxymethampheta (MDMA), which the Company is developing for the treatment of autism spectrum disorder (ASD).

MMQ Intrinsic Value
2.177 EUR
Overvaluation 68%
Intrinsic Value
Price

See Also

What is Mind Medicine (MindMed) Inc's Other?
Other
506k USD

Based on the financial report for Sep 30, 2024, Mind Medicine (MindMed) Inc's Other amounts to 506k USD.

Back to Top